Literature DB >> 1614741

Praziquantel: physiological evidence for its site(s) of action in magnesium-paralysed Schistosoma mansoni.

K L Blair1, J L Bennett, R A Pax.   

Abstract

The mechanism whereby praziquantel produces a contraction and subsequent flaccid paralysis (a loss of sensitivity to subsequent stimuli) of Schistosoma mansoni in a medium containing an elevated Mg2+:Ca2+ ratio was investigated. In RPMI, praziquantel produced a concentration-dependent tonic contraction of the parasite with an EC50 of 200 nM. Magnesium inhibited the contraction in such a manner as to convert the tonic contraction to a phasic one without altering the peak force generated. The Mg(2+)-dependent block was non-competitive with praziquantel but was competitive with extracellular Ca2+, ratios of 7.5:1;Mg2+:Ca2+ being needed to inhibit the tonic contraction and to induce flaccid paralysis. Flaccid paralysis was associated with a reduced ability of the parasite to take up 45Ca2+ from the bath compared to parasites that had not entered into flaccid paralysis and flaccid paralysis was reversible. Recovery from flaccid paralysis was accelerated by treatments that are expected to increase Ca2+ uptake by the parasite. At a concentration of 500 nM, praziquantel produced 2 distinct phasic contractions in intact parasites incubated in an elevated [Mg2+] medium but only 1 phasic contraction in parasites lacking their surface tegumental membranes. In zero Ca2+ I-RPMI, 10 microM praziquantel produced a phasic contraction of intact parasites but did not stimulate contraction of detegumented parasites until Ca2+ was reintroduced into the bath. These results indicate that praziquantel interacts with specific Ca(2+)-permeable sites in the tegumental and sarcoplasmic membranes of the parasite and that under these conditions of elevated Mg2+:Ca2+ ratios, these sites become blocked by Mg2+, leading to flaccid paralysis of the parasite.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1614741     DOI: 10.1017/s0031182000060807

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  7 in total

1.  Reduction in hookworm infection after praziquantel treatment among children and young adults in Leyte, the Philippines.

Authors:  Julia G Shaw; Nitin Aggarwal; Luz P Acosta; Mario A Jiz; Hai-Wei Wu; Tjalling Leenstra; Hannah M Coutinho; Remigio M Olveda; Jonathan D Kurtis; Stephen T McGarvey; Jennifer F Friedman
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

2.  Time course of the effect of praziquantel on Schistosoma mansoni attachment in vitro: comparison with its effects on worm length and motility.

Authors:  S P da Silva; F Noël
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

3.  RNAi silencing of calcium-regulated heat-stable protein of 24 kDa in Schistosoma japonicum affects parasite growth.

Authors:  Xiang Zou; Ya-mei Jin; Ping-ping Liu; Qi-jin Wu; Jin-ming Liu; Jiao-jiao Lin
Journal:  Parasitol Res       Date:  2010-11-18       Impact factor: 2.289

Review 4.  Ca²⁺ channels and praziquantel: a view from the free world.

Authors:  John D Chan; Magdalena Zarowiecki; Jonathan S Marchant
Journal:  Parasitol Int       Date:  2012-12-16       Impact factor: 2.230

5.  Praziquantel affects the regulatory myosin light chain of Schistosoma mansoni.

Authors:  Munirathinam Gnanasekar; Ashok M Salunkhe; A Krishna Mallia; Yi Xun He; Ramaswamy Kalyanasundaram
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

Review 6.  The Journey to Discovering a Flatworm Target of Praziquantel: A Long TRP.

Authors:  Sang-Kyu Park; Jonathan S Marchant
Journal:  Trends Parasitol       Date:  2019-11-29

7.  The anthelmintic drug praziquantel activates a schistosome transient receptor potential channel.

Authors:  Sang-Kyu Park; Gihan S Gunaratne; Evgeny G Chulkov; Francie Moehring; Paul McCusker; Peter I Dosa; John D Chan; Cheryl L Stucky; Jonathan S Marchant
Journal:  J Biol Chem       Date:  2019-10-25       Impact factor: 5.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.